Discontinuing Multifocal Contacts Does Not Diminish Treatment Effect in Myopia
By Elana Gotkine HealthDay Reporter
TUESDAY, Jan. 21, 2025 -- No evidence is seen for loss of treatment effect after discontinuing soft multifocal contact lenses in older teenagers with myopia, according to a study published online Jan. 16 in JAMA Ophthalmology.
David A. Berntsen, O.D., Ph.D., from the University of Houston College of Optometry, and colleagues examined whether there is a loss of treatment effect (rebound) after discontinuing soft multifocal contact lenses in the Bifocal Lenses in Nearsighted Kids 2 (BLINK2) cohort study involving 248 children (aged 11 to 17 years at baseline) with myopia who completed the BLINK randomized clinical trial. All children in the BLINK2 study wore high-add (+2.50 diopter [D]) multifocal soft contact lenses for two years and single-vision soft contact lenses during the third year to ascertain whether rebound occurred.
The researchers found that the mean axial length and spherical equivalent refractive error were 25.2 mm and −3.40 D, respectively, at baseline. Regardless of the original BLINK treatment assignment, axial elongation increased by 0.03 mm/year after participants switched from multifocal to single-vision contact lenses, and myopia progression increased by −0.17 D per year after switching to single-vision contact lenses. Throughout BLINK2, there continued to be a difference in axial length and refractive error based on the BLINK Study treatment assignment; shorter eyes and less myopia were seen in the original high-add group than in the original medium-add (+1.50 D) and single-vision groups.
These results "support fitting children with multifocal contact lenses for myopia control at a younger age and, when possible, continuing treatment until the late teenage years when myopia progression has naturally slowed," the authors write.
Several authors disclosed ties to the ophthalmic industry.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Read this next
FDA Approves Vizz Eye Drops to Improve Near Vision in Adults
TUESDAY, Aug. 5, 2025 -- The U.S. Food and Drug Administration has approved Vizz 1.44 percent (aceclidine ophthalmic solution) for the treatment of presbyopia in adults. Vizz is...
Corticosteroids Not Superior to Placebo for Add-On Treatment of Bacterial Keratitis
MONDAY, July 28, 2025 -- For the treatment of bacterial keratitis, adjunctive corticosteroids are not superior to placebo and adjunctive corneal cross-linking (CXL) is associated...
Indicators of Neuropathic Ocular Pain Identified After LASIK
TUESDAY, July 22, 2025 -- In a study published in the August issue of the American Journal of Ophthalmology, diagnostic indicators are identified for confirming chronic...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.